- Home
- FBIO
as 07-26-2024 4:00pm EST
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | BAY HARBOR ISLANDS |
| Market Cap: | 34.1M | IPO Year: | N/A |
| Target Price: | $16.33 | AVG Volume (30 days): | 287.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.10 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.24 - $9.00 | Next Earning Date: | 08-12-2024 |
| Revenue: | $85,114,000 | Revenue Growth: | 32.48% |
| Revenue Growth (this year): | -10.79% | Revenue Growth (next year): | 70.41% |
Latest Fortress Biotech Inc. News
FBIO Breaking Stock News: Dive into FBIO Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027
GlobeNewswire
2 days ago
Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
Argus Research
11 days ago
Daily – Vickers Top Buyers & Sellers for 07/16/2024
Zacks
11 days ago
Here Is Why Bargain Hunters Would Love Fast-paced Mover Fortress Biotech (FBIO)
GlobeNewswire
11 days ago
GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research
GlobeNewswire
15 days ago
Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors
GlobeNewswire
21 days ago
Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
GlobeNewswire
24 days ago
Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Compare FBIO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FBIO Fortress Biotech Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.